Advertisement

Biomedical Microdevices

, 20:105 | Cite as

Multimodal imaging of the tumor microenvironment and biological responses to immune therapy

  • Alexander M. Saucedo
  • Jorge De La Cerda
  • Hiroo Suami
  • Rita E. SerdaEmail author
Article
  • 113 Downloads

Abstract

Beyond heterogeneous cancer cells, the tumor microenvironment includes stromal and immune cells, blood vessels, extracellular matrix and biologically active molecules. Abnormal signaling, uncontrolled proliferation and high interstitial pressure all contribute to a chaotic, non-hierarchical vascular organization. Using an immune competent 4T1 breast adenocarcinoma murine model, this study fully characterizes the architecture and immunocyte milieu of the tumor microenvironment. Heterogeneous vessel distribution, chaotic connectivity, limited perfusion, cancer cell density, immune phenotype, and biological responses to immune therapy are presented. Cancer cell density mirrored the distribution of large, perfusable vessels, both predominately in the tumor periphery. Intratumoral administration of the proinflammatory cytokine IL-12 led to an increase in CD45+ leukocytes, with a specific increase in CD4+ and CD8+ T cells, and a decrease in the percentage of Gr-llo myeloid-derived suppressor cells. Concomitantly, serum G-CSF, IL-10 and VEGF decreased, while CXCR9 and interferon gamma increased. The distribution pattern of infiltrating monocytes/macrophages, visualized using a fluorescent perfluorocarbon emulsion, indicated that macrophages predominately localize in the vicinity of large blood vessels. Electron microscopy supports the presence of dense tumor cell masses throughout the tumor, with the largest vessels present in the surrounding mammary fat pad. Overall, large vessels in the 4T1 tumor periphery support high, localized vascular perfusion and myeloid accumulation. The pro-inflammatory cytokine IL-12 stimulated a transition towards T helper 1 cytokines in serum, supporting suppression of tumor growth and angiostatic conditions.

Keywords

Tumor vasculature computed tomography Electron microscopy Interleukin 12 Magnetic resonance imaging 

Notes

Acknowledgements

We wish to acknowledge use of the Animal Resource Facilities at the University of New Mexico, Houston Methodist and Baylor College of Medicine. Imaging equipment and tissue processing were provided by the UNM Animal Models and Microscopy Facilities and the Human Tissue Repository and Tissue Analysis Facility, supported by the UNM Cancer Center Support Grant NCI 2P30 CA118100-11, PI Willman, C. The UNM Center for Micro-Engineered Materials Electron Microscopy Facility provided the FEI Quanta 3D Dual Beam FIB-FEGSEM for tissue electron microscopy. We are grateful to the MD Anderson Cancer Center Small Animal Imaging Facility, the Houston Methodist PET-CT Facility, and Baylor College of Medicine Small Animal MRI Core for assistance with in vivo imaging studies.

References

  1. N. Abdel-Wahab, A. Alshawa, M.E. Suarez-Almazor, Adverse events in Cancer immunotherapy. Adv. Exp. Med. Biol. 995, 155–174 (2017)CrossRefGoogle Scholar
  2. H.K. Bhattacharjee, V.K. Bansal, B. Nepal, S. Srivastava, A.K. Dinda, M.C. Misra, Is interleukin 10 (IL10) expression in breast Cancer a marker of poor prognosis? Indian J Surg Oncol. 7, 320–325 (2016)CrossRefGoogle Scholar
  3. H. Bronger, J. Singer, C. Windmuller, U. Reuning, D. Zech, C. Delbridge, et al., CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br. J. Cancer 115, 553–563 (2016)CrossRefGoogle Scholar
  4. L. Grabowska-Derlatka, P. Derlatka, P. Palczewski, A. Danska-Bidzinska, R. Pacho, Differentiation of ovarian cancers from borderline ovarian tumors on the basis of evaluation of tumor vascularity in multi-row detector computed tomography--comparison with histopathology. Int. J. Gynecol. Cancer 23, 1597–1602 (2013)CrossRefGoogle Scholar
  5. R.S. Heist, D.G. Duda, D.V. Sahani, M. Ancukiewicz, P. Fidias, L.V. Sequist, et al., Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 112, 1547–1552 (2015)CrossRefGoogle Scholar
  6. R.K. Jain, Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin. Oncol. 29, 3–9 (2002)CrossRefGoogle Scholar
  7. F. Kroschinsky, F. Stolzel, S. von Bonin, G. Beutel, M. Kochanek, M. Kiehl, et al., New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care 21, 89 (2017)CrossRefGoogle Scholar
  8. D.W. Lee, R. Gardner, D.L. Porter, C.U. Louis, N. Ahmed, M. Jensen, et al., Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014)CrossRefGoogle Scholar
  9. A. Mielgo, M.C. Schmid, Impact of tumour associated macrophages in pancreatic cancer. BMB Rep. 46, 131–138 (2013)CrossRefGoogle Scholar
  10. L.L. Munn, Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov. Today 8, 396–403 (2003)CrossRefGoogle Scholar
  11. G. Song, D.B. Darr, C.M. Santos, M. Ross, A. Valdivia, J.L. Jordan, et al., Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 20, 6083–6095 (2014)CrossRefGoogle Scholar
  12. C.S. Springer Jr., X. Li, L.A. Tudorica, K.Y. Oh, N. Roy, S.Y. Chui, et al., Intratumor mapping of intracellular water lifetime: Metabolic images of breast cancer? NMR Biomed. 27, 760–773 (2014)CrossRefGoogle Scholar
  13. Z. Starosolski, C.A. Villamizar, D. Rendon, M.J. Paldino, D.M. Milewicz, K.B. Ghaghada, et al., Ultra high-resolution in vivo computed tomography imaging of mouse Cerebrovasculature using a long circulating blood Pool contrast agent. Sci. Rep. 5, 10178 (2015)CrossRefGoogle Scholar
  14. T.D. Tlsty, Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97–104 (2001)CrossRefGoogle Scholar
  15. J.D. Waight, Q. Hu, A. Miller, S. Liu, S.I. Abrams, Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6, e27690 (2011)CrossRefGoogle Scholar
  16. M. Welter, K. Bartha, H. Rieger, Emergent vascular network inhomogeneities and resulting blood flow patterns in a growing tumor. J. Theor. Biol. 250, 257–280 (2008)MathSciNetCrossRefGoogle Scholar
  17. C.J. Whatcott, R.G. Posner, D.D. Von Hoff, H. Han, in Pancreatic Cancer and Tumor Microenvironment, ed. by P. J. Grippo, H. G. Munshi. Desmoplasia and chemoresistance in pancreatic Cancer Trivandrum (India) 2012Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Alexander M. Saucedo
    • 1
  • Jorge De La Cerda
    • 2
  • Hiroo Suami
    • 3
    • 4
  • Rita E. Serda
    • 1
    • 5
    • 6
    Email author
  1. 1.Michael E. DeBakey Department of SurgeryBaylor College of MedicineHoustonUSA
  2. 2.Small Animal Imaging ResourceUT MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Plastic SurgeryUT MD Anderson Cancer CenterHoustonUSA
  4. 4.Medicine and Health SciencesMacquarie UniversitySydneyAustralia
  5. 5.Department of NanomedicineHouston MethodistHoustonUSA
  6. 6.Molecular Medicine, Internal MedicineUniversity of New Mexico Health Science CenterAlbuquerqueUSA

Personalised recommendations